Jiang Fu-Qiang, Lu Wei, Yang Chao, Du Peng, Ma Jun-Peng, Yang Jian, Xie Peng, Zhang Zhe
Cancer Biomark. 2017 Jul 19;20(1):17-22. doi: 10.3233/CBM-160508.
Hepatic cell carcinoma (HCC) is more common in clinical practice, and has high malignant degree.
This study aims to analyze the curative effect of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation (RFA) in treating hepatic cell carcinoma (HCC) and its effect on serum markers.
A total of 106 cases of patients with hepatic cell carcinoma treated in our hospital were randomly divided into two groups: observation group and control group. Patients in the observation group (53 cases) received transcatheter arterial chemoembolization combined with radiofrequency ablation therapy, while subjects in the control group (53 cases) received transcatheter arterial chemoembolization therapy. Differences in the overall effect, indicators of inflammation and oxidative stress, tumor activity-related indicators and tumor recurrence-related indicators between these two groups were compared.
At one and two weeks after treatment, the number of cases of CR and PR in the observation group was higher than that in the control group, the number of cases of SD was not different from that in the control group, and the number of cases of PD was lower than that in the control group. At two weeks after treatment, differences in serum MDA, SOD, GSH, CRP, TNF-α and ESR between the two groups were significant. However, serum EC, VEGF, MMP, AFP, CA199 and GGT content was significantly lower in the observation group than that in the control group.
Transcatheter arterial chemoembolization combined with radiofrequency ablation therapy can effectively control the growth of liver cancer lesions, reduce the levels of tumor-related serum markers, and inhibit the activity of tumor cells.
肝细胞癌（HCC）在临床实践中较为常见，且恶性程度高。
本研究旨在分析经导管动脉化疗栓塞术（TACE）联合射频消融术（RFA）治疗肝细胞癌（HCC）的疗效及其对血清标志物的影响。
将我院收治的106例肝细胞癌患者随机分为两组：观察组和对照组。观察组（53例）患者接受经导管动脉化疗栓塞联合射频消融治疗，而对照组（53例）患者接受经导管动脉化疗栓塞治疗。比较两组患者的总体疗效、炎症和氧化应激指标、肿瘤活性相关指标以及肿瘤复发相关指标的差异。
治疗后1周和2周，观察组CR和PR病例数高于对照组，SD病例数与对照组无差异，PD病例数低于对照组。治疗后2周时，两组血清MDA、SOD、GSH、CRP、TNF-α和ESR差异有统计学意义。然而，观察组血清EC、VEGF、MMP、AFP、CA199和GGT含量明显低于对照组。
经导管动脉化疗栓塞联合射频消融治疗可有效控制肝癌病灶生长，降低肿瘤相关血清标志物水平，抑制肿瘤细胞活性。
